Sophie Bergeron Kermelly, MD
Laval University, Hôtel-Dieu de Lévis; Quebec City, QC

Session Description

COPD is now recognized as a heterogeneous entity with multiple treatable traits. Eosinophilic COPD is a well-defined phenotype. This phenotype could be associated with an increased number of acute exacerbations and a worsen prognostic. Three major randomized clinical trials looked at biologic agents in COPD to reduce eosinophilic inflammation. These trials reported mitigated results. To carefully address and assess this phenotype among COPD patients in clinical practice is important in order to identify which COPD patients could benefit from these therapies.

Learning Objectives

At the end of this presentation, attendees will be able to:

  • Identify eosinophilic COPD phenotype
  • Recognize the burden of the disease in eosinophilic COPD
  • Analyze and apply main Biologics trials in COPD to guide clinical practice


CanMEDs Roles: Health Advocate, Leader, Medical Expert, Scholar